stockrow
Saturday 7 November 2026
Export MLEC’s income statement to Excel — free account
Moolec Science SA
MLEC Healthcare Biotechnology
Moolec Science SA’s revenue for fiscal 2025 (year ended June 2025) was $333.6 million, up 5,830.7% from fiscal 2024.
- Revenue
- +948.4%
- EPS
- −20.0%
- Free cash flow
- +4.48%
Quarter to December 2025, against a year earlier
0.85
0.00
0.00%
Follow MLEC
Alert me
| Dec '25 | Dec '24 | Sep '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | 3.98 | 6.25 | 7.51 | |
P/FCF ratio |
— | 1.72 | 2.21 | 2.87 | |
P/Operating CF |
— | (35.02) | (30.21) | 0.88 | |
P/B ratio |
— | 11.15 | 5.97 | 0.17 | |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 | |
EV/Sales |
— | 6.53 | 9.61 | 75.61 | |
EV/EBITDA |
— | 1.37 | 1.40 | 11.43 | |
EV/Operating CF |
— | 1.18 | 1.30 | 10.75 | |
EV/FCF |
— | 2.82 | 3.40 | 28.92 | |
Quick Ratio |
0.08 | 0.72 | 0.71 | 0.73 | |
Current Ratio |
0.15 | 1.48 | 1.51 | 1.03 | |
Net Debt/EBITDA |
0.00 | (11.35) | (10.30) | 9.00 | |
Debt/Assets |
64.22% | 69.80% | 67.28% | 47.45% | |
Debt/Equity |
4.37 | 7.83 | 3.85 | 1.80 | |
Asset Turnover |
0.00 | 0.30 | 0.20 | 0.01 | |
Operating CF/Net income |
0.00 | 0.37 | 0.59 | (18.87) | |
Capex/Depreciation |
(1.49) | (1.00) | (0.18) | (1.43) | |
Interest Coverage |
— | (3.10) | (3.82) | 0.68 | |
Research and Development Expense of Revenue |
— | 11.28% | 27.33% | 1,055.18% | |
Selling, General and Administrative Expense of Revenue |
— | 41.93% | 113.64% | 7,926.10% | |
Intangible Assets out of Total Assets |
0.71 | 0.30 | 0.28 | 0.30 | |
Share Based Compensation of Revenue |
0.00% | (22.70%) | 18.34% | 824.87% | |
Graham Net Nets |
— | (0.61) | (0.46) | (6.20) | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (27.08%) | (23.50%) | (17.71%) | |
Free Cash Flow Yield |
— | 58.17% | 45.18% | 34.83% | |
Revenue per Share |
— | 10.17 | 6.03 | 6.01 | |
Operating CF per Share |
0.00 | (3.43) | (4.36) | 188.68 | |
Capex per Share |
0.00 | (1.15) | (0.23) | (96.86) | |
Free Cash Flow per Share |
0.00 | (4.58) | (4.60) | 91.82 | |
Cash per Share |
0.00 | 7.43 | 13.99 | 266.83 | |
Shareholders Equity per Share |
0.00 | 10.76 | 22.07 | 985.90 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 10.76 | 22.07 | 985.90 | |
Free Cash Flow |
(2.55) | (1.19) | (1.19) | 23.28 | |
Working Capital |
(52.69) | 3.09 | 3.79 | 10.80 | |
Capital Expenditures |
(1.50) | (0.30) | (0.06) | (24.56) | |
Net Current Asset Value |
(79.01) | (19.04) | (15.71) | (261.63) | |
EV/EBIT |
— | 2.67 | 2.69 | 22.05 | |
Capex to Sales |
0.00 | 0.11 | 0.04 | 16.13 | |
Price to Operating Income |
— | 1.63 | 1.75 | 2.19 | |
| Other line items | |||||
Average Receivables |
2.94 | 1.97 | 1.72 | 123.01 | |
Average Payables |
5.17 | 3.79 | 5.22 | 88.21 | |
Average Inventory |
2.19 | 2.67 | 2.98 | 63.34 | |
Average Assets |
64.67 | 26.35 | 27.53 | 486.94 | |
Average Common Equity |
10.91 | 4.74 | 7.29 | 130.05 |
Columns are period end dates · fundamentals updated 26 Oct 2026